Find, compare & contact
Menadione bisulfite
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Menadione bisulfite API 130-36-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Menadione bisulfite. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Menadione bisulfite
- Synonyms:
- Cas Number:
- 130-36-9
- DrugBank number:
- DB15944
- Unique Ingredient Identifier:
- I2BE1ZEN8I
General Description:
Menadione bisulfite is a chemical compound identified by the CAS number 130-36-9. It is known for its distinct pharmacological properties and applications.
Categories:
Menadione bisulfite is categorized under the following therapeutic classes: Antifibrinolytic Agents, Coagulants, Diet, Food, and Nutrition, Diterpenes, Fibrin Modulating Agents, Food, Hematologic Agents, Hemostatics, Micronutrients, Naphthalenes, Naphthoquinones, Physiological Phenomena, Phytol, Quinones, Terpenes, Vitamin K, Vitamins, Vitamins (Fat Soluble). These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Menadione bisulfite is a type of Antifibrinolytics
Antifibrinolytics belong to a vital category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the medical field. These compounds play a crucial role in preventing excessive bleeding by inhibiting the breakdown of blood clots. By promoting clot stability, antifibrinolytics help control bleeding, particularly in situations where there is a risk of uncontrolled hemorrhage.
One well-known antifibrinolytic agent is tranexamic acid, which is widely employed in various medical procedures, including surgery, trauma management, and dental procedures. This API works by binding to plasminogen, a protein involved in the dissolution of blood clots, and preventing its conversion to plasmin, the enzyme responsible for clot degradation.
Another prominent antifibrinolytic is aminocaproic acid, which acts in a similar manner to tranexamic acid. It competitively inhibits the activation of plasminogen, thereby preserving the integrity of formed clots.
Antifibrinolytics find applications in several medical specialties, such as orthopedics, cardiovascular surgery, and gynecology. They are particularly valuable in managing bleeding disorders, such as hemophilia and menorrhagia, as well as in minimizing blood loss during major surgical procedures.
As with any pharmaceutical API, the production and use of antifibrinolytics require adherence to strict quality control standards and regulatory guidelines to ensure their safety and efficacy. Healthcare professionals should carefully assess each patient's condition and consider potential contraindications or interactions before prescribing or administering antifibrinolytic medications.
In conclusion, antifibrinolytics play a crucial role in preventing excessive bleeding by inhibiting clot breakdown. These pharmaceutical APIs, such as tranexamic acid and aminocaproic acid, are widely used in various medical procedures and provide valuable therapeutic options for managing bleeding disorders and minimizing blood loss during surgeries.
